{"entity":{"id":"nct06581432","kind":"trial","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","aka":[],"tldr":"A phase 2 trial of Zongertinib in advanced solid tumours, run by Boehringer Ingelheim, now recruiting.","summary":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations is a phase 2 interventional study registered as NCT06581432 by Boehringer Ingelheim, with 588 participants planned, started 2024-10-11 and due to reach its primary completion in 2028-11-30. Interventions recorded: Zongertinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06581432","url":"https://clinicaltrials.gov/study/NCT06581432"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["zongertinib"],"companies":["boehringer-ingelheim"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06581432","phase":"2","setting":"Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours","sponsor":"Boehringer Ingelheim","enrolled":588,"outcomes":[]},"route":"/trials/nct06581432/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/"}],"company":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/"}]}}